Respiratory Microbiota and Immune Response in CVID

Purpose

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aims to establish cutting-edge approaches to study pulmonary biology in CVID and apply novel bioinformatics strategies to study complex interactions among microbes and host cells by direct sampling of the respiratory tract. The central hypothesis for this research is that antibody (Ab) deficiency in CVID alters respiratory microbiota and host interactions to drive pulmonary disease.

Condition

  • CVID

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients with primary antibody deficiency diagnosed by their treating physician - Controls will not have a diagnosis of immunodeficiency of any sort - Male and female patients will be enrolled evenly

Exclusion Criteria

  • Patients who self identify as pregnant - Patients with asthma or chronic obstructive pulmonary disease (COPD) that are not well controlled clinically

Study Design

Phase
Study Type
Observational
Observational Model
Case-Control
Time Perspective
Cross-Sectional

Arm Groups

ArmDescriptionAssigned Intervention
Antibody deficient participants Provider referred patients that have antibody deficiency.
Controls Patients without antibody deficiency from the allergy and immunology clinic at Boston Medical Center and from healthy volunteers at the BU School of Medicine.

Recruiting Locations

Boston Medical Center
Boston, Massachusetts 02118
Contact:
Paul J Maglione, MD PhD
617-358-0913
pmaglion@bu.edu

More Details

Status
Recruiting
Sponsor
Boston University

Study Contact

Paul J Maglione, MD PhD
617 358 0913
pmaglion@bu.edu